Clinical trial
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
NCT00324740 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00324740 |
|---|---|
| Title | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer |
| Official title | A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | vorinostat, isotretinoin |
| Enrollment | 14 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2011 |
| Completion | May 1, 2014 |
| First posted | May 11, 2006 |
| Last update posted | Feb 23, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: